Mycomed Ingredients – Clinical studies/Trials

Clinical Study-5

Inhibitory effect on in vitro LDL oxidation and HMG Co-A reductase activity of the liquid partitioned fractions of Hericium erinaceus (Bull.) Persoon (lion’s manemushroom)

[Biomed Res Int. 2014;2014:828149. doi: 10.1155/2014/828149. Epub 2014 May 13]
Rahman MA1Abdullah N2Aminudin N2

Abstract

Oxidation of low-density lipoprotein (LDL) has been strongly suggested as the key factor in the pathogenesis of atherosclerosis. Mushrooms have been implicated in having preventive effects against chronic diseases due especially to their antioxidant properties. In this study, in vitro inhibitory effect of Hericium erinaceus on LDL oxidation and the activity of the cholesterol biosynthetic key enzyme, 3-hydroxy-3-methyl glutaryl coenzyme A (HMG Co-A) reductase, was evaluated using five liquid-liquid solvent fractions consisting of methanol : dichloromethane (M : DCM), hexane (HEX), dichloromethane (DCM), ethyl acetate (EA), and aqueous residue (AQ). The hexane fraction showed the most inhibition of oxidation of human LDL as reflected by the increased lag time (120 mins) for the formation of conjugated diene (CD) at 1 µg/mL and decreased production (68.28%, IC50 0.73 mg/mL) of thiobarbituric acid reactive substances (TBARS) at 1 mg/mL. It also mostly inhibited (59.91%) the activity of the HMG Co-A reductase at 10 mg/mL. The GC-MS profiling of the hexane fraction identified the presence of myconutrients: inter alia, ergosterol and linoleic acid. Thus, hexane fraction of Hericium erinaceus was found to be the most potent in vitro inhibitor of both LDL oxidation and HMG Co-A reductase activity having therapeutic potential for the prevention of oxidative stress-mediated vascular diseases.

PMID:24959591
PMCID:PMC4052699
DOI:10.1155/2014/828149
[Indexed for MEDLINE]